Schweiz -
italiensk -
Swissmedic (Swiss Agency for Therapeutic Products)
kesimpta soluzione iniettabile in penna preriempita
novartis pharma schweiz ag - ofatumumabum - soluzione iniettabile in penna preriempita - ofatumumabum 20 mg, argininum, natrii acetas trihydricus, natrii chloridum, polysorbatum 80, dinatrii edetas, acidum hydrochloridum 25 per centum, aqua ad iniectabile q.s. ad solutionem pro 0.4 ml corresp. natrium 0.92 mg. - multiple sklerose - biotechnologika
Italien -
italiensk -
AIFA (Agenzia Italiana del Farmaco)
carteol
sifi s.p.a. - carteololo - carteololo
Italien -
italiensk -
AIFA (Agenzia Italiana del Farmaco)
timogel
laboratoires thea - timololo - timololo
Italien -
italiensk -
AIFA (Agenzia Italiana del Farmaco)
fortidose
bausch & lomb-iom s.p.a. - carteololo - carteololo
Italien -
italiensk -
AIFA (Agenzia Italiana del Farmaco)
mitoxantrone accord
accord healthcare, s.l.u. - mitoxantrone - mitoxantrone
Den Europæiske Union -
italiensk -
EMA (European Medicines Agency)
aubagio
sanofi winthrop industrie - teriflunomide - sclerosi multipla - immunosoppressori selettivi - aubagio is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).
Den Europæiske Union -
italiensk -
EMA (European Medicines Agency)
fampyra
biogen netherlands b.v. - fampridine - sclerosi multipla - altri farmaci sul sistema nervoso - fampyra è indicato per il miglioramento della deambulazione nei pazienti adulti con sclerosi multipla con disabilità motoria (expanded disability status scale 4-7).
Den Europæiske Union -
italiensk -
EMA (European Medicines Agency)
tysabri
biogen netherlands b.v. - natalizumab - sclerosi multipla - immunosoppressori selettivi - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 e 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.